<DOC>
	<DOCNO>NCT02826642</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability potential efficacy IDH305 standard treatment newly diagnose IDH1R132 mutant acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>A Dose Finding Study IDH305 With Standard Care IDH1 Mutant Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Previously untreated AML . Patients untreated , high high risk MDS ( accord rIPSS equivalent ) also permit Arm 2 . Documentation IDH1R132 mutation tumor ECOG performance status â‰¤ 2 Clinically fit standard care medication per protocol . Prior treatment AML MDS Any severe uncontrolled medical condition would prevent patient 's participation clinical study due safety concern compliance clinical study procedure presence clinically significant cardiac , respiratory , gastrointestinal , renal , hepatic neurological disease . Acute Promyelocytic Leukemia Women pregnant lactate Other protocoldefined Inclusion/Exclusion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>newly diagnose acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>myeloid dysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>IDH305</keyword>
	<keyword>standard care IDH1 mutant acute myeloid leukemia</keyword>
</DOC>